

William J Muller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9578419/publications.pdf>

Version: 2024-02-01

124
papers

12,449
citations

31976
53
h-index

24982
109
g-index

124
all docs

124
docs citations

124
times ranked

15828
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Emergence of β 1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment. <i>Oncogene</i> , 2022, 41, 527-537. | 5.9 | 9 |
| 2 | Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 14 |
| 3 | ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. <i>Nature Communications</i> , 2022, 13, 2011. | 12.8 | 29 |
| 4 | Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer. <i>Endocrinology</i> , 2022, 163, . | 2.8 | 6 |
| 5 | Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. <i>Oncogene</i> , 2022, 41, 3445-3451. | 5.9 | 2 |
| 6 | Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. <i>Oncogene</i> , 2021, 40, 475-491. | 5.9 | 91 |
| 7 | Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , . | | 2 |
| 8 | Pharmacological or genetic inhibition of iNOS prevents cachexia-mediated muscle wasting and its associated metabolism defects. <i>EMBO Molecular Medicine</i> , 2021, 13, e13591. | 6.9 | 9 |
| 9 | Fish oil supplementation increases expression of mammary tumor apoptosis mediators and reduces inflammation in an obesity-associated HER-2 breast cancer model. <i>Journal of Nutritional Biochemistry</i> , 2021, 95, 108763. | 4.2 | 9 |
| 10 | Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and β PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4670-4681. | 7.0 | 31 |
| 11 | An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. <i>Bone Research</i> , 2020, 8, 28. | 11.4 | 8 |
| 12 | Her-2 Breast Cancer Outcomes Are Mitigated by Consuming n-3 Polyunsaturated, Saturated, and Monounsaturated Fatty Acids Compared to n-6 Polyunsaturated Fatty Acids. <i>Nutrients</i> , 2020, 12, 3901. | 4.1 | 5 |
| 13 | In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. <i>Advances in Cancer Research</i> , 2020, 147, 189-228. | 5.0 | 7 |
| 14 | Rheb1-Independent Activation of mTORC1 in Mammary Tumors Occurs through Activating Mutations in mTOR. <i>Cell Reports</i> , 2020, 31, 107571. | 6.4 | 10 |
| 15 | Tetraspanin CD9 is Regulated by miR-518f-5p and Functions in Breast Cell Migration and In Vivo Tumor Growth. <i>Cancers</i> , 2020, 12, 795. | 3.7 | 11 |
| 16 | Point-activated ESR1 ^{Y541S} has a dramatic effect on the development of sexually dimorphic organs. <i>Genes and Development</i> , 2020, 34, 1304-1309. | 5.9 | 10 |
| 17 | An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 2901. | 12.8 | 24 |
| 18 | Functional Redundancy between β 1 and β 3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. <i>Cell Reports</i> , 2019, 29, 589-602.e6. | 6.4 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. <i>Cell Reports</i> , 2019, 29, 249-257.e8. | 6.4 | 29 |
| 20 | Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases. <i>Cancer Research</i> , 2019, 79, 21-32. | 0.9 | 32 |
| 21 | CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 77 |
| 22 | Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. <i>Molecular Cancer Research</i> , 2018, 16, 894-908. | 3.4 | 6 |
| 23 | Marine fish oil is more potent than plant-based n-3 polyunsaturated fatty acids in the prevention of mammary tumors. <i>Journal of Nutritional Biochemistry</i> , 2018, 55, 41-52. | 4.2 | 23 |
| 24 | <i>In vivo</i> evidence supporting a metastasis suppressor role for <i>Stard13</i> (<i>Dlc2</i>) in <i>ErbB2</i> (<i>Neu</i>) oncogene induced mouse mammary tumors. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 182-191. | 2.8 | 13 |
| 25 | The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. <i>Cell Reports</i> , 2018, 23, 1476-1490. | 6.4 | 127 |
| 26 | Translational and HIF-1 α -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018, 28, 817-832.e8. | 16.2 | 61 |
| 27 | Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. <i>Nature Communications</i> , 2018, 9, 2547. | 12.8 | 63 |
| 28 | Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. <i>Oncotarget</i> , 2018, 9, 33382-33395. | 1.8 | 7 |
| 29 | β -Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E707-E716. | 7.1 | 22 |
| 30 | The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. <i>Nature Communications</i> , 2017, 8, 14638. | 12.8 | 52 |
| 31 | Stat3 regulates centrosome clustering in cancer cells via Stathmin/PLK1. <i>Nature Communications</i> , 2017, 8, 15289. | 12.8 | 36 |
| 32 | Progressive polarity loss and luminal collapse disrupt tissue organization in carcinoma. <i>Genes and Development</i> , 2017, 31, 1573-1587. | 5.9 | 45 |
| 33 | Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. <i>Breast Cancer Research</i> , 2017, 19, 74. | 5.0 | 55 |
| 34 | Tumoral Vitamin D Synthesis by CYP27B1 1 α -Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF- κ B Modulation. <i>Endocrinology</i> , 2016, 157, 2204-2216. | 2.8 | 37 |
| 35 | The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. <i>Breast Cancer Research</i> , 2016, 18, 131. | 5.0 | 50 |
| 36 | Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast Cancers. <i>Cancer Research</i> , 2016, 76, 4752-4764. | 0.9 | 71 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , 2016, 76, 2662-2674. | 0.9 | 31 |
| 38 | STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. <i>Cancer Research</i> , 2016, 76, 1416-1428. | 0.9 | 87 |
| 39 | Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. <i>Breast Cancer Research</i> , 2015, 17, 7. | 5.0 | 14 |
| 40 | Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Biology</i> , 2015, 35, 4069-4082. | 2.3 | 33 |
| 41 | Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. <i>Breast Cancer Research</i> , 2014, 16, R11. | 5.0 | 21 |
| 42 | ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction. <i>Molecular and Cellular Biology</i> , 2014, 34, 4232-4243. | 2.3 | 10 |
| 43 | Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model. <i>BMC Cancer</i> , 2014, 14, 509. | 2.6 | 12 |
| 44 | Cancer Affects microRNA Expression, Release, and Function in Cardiac and Skeletal Muscle. <i>Cancer Research</i> , 2014, 74, 4270-4281. | 0.9 | 44 |
| 45 | Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer. <i>Cancer Cell</i> , 2013, 24, 213-228. | 16.8 | 678 |
| 46 | LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer & Metabolism</i> , 2013, 1, 18. | 5.0 | 44 |
| 47 | β -Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , 2013, 73, 4474-4487. | 0.9 | 65 |
| 48 | Bcl3 Selectively Promotes Metastasis of ERBB2-Driven Mammary Tumors. <i>Cancer Research</i> , 2013, 73, 745-755. | 0.9 | 63 |
| 49 | p120-catenin is essential for terminal end bud function and mammary morphogenesis. <i>Development (Cambridge)</i> , 2012, 139, 1754-1764. | 2.5 | 39 |
| 50 | Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis. <i>Cancer Research</i> , 2012, 72, 3080-3090. | 0.9 | 23 |
| 51 | Loss of the 14-3-3 β Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression. <i>Cancer Discovery</i> , 2012, 2, 68-81. | 9.4 | 26 |
| 52 | PGC-1 α Promotes the Growth of ErbB2/Neu-Induced Mammary Tumors by Regulating Nutrient Supply. <i>Cancer Research</i> , 2012, 72, 1538-1546. | 0.9 | 45 |
| 53 | Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2808-2813. | 7.1 | 50 |
| 54 | The p110 α and p110 β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. <i>Genes and Development</i> , 2012, 26, 1573-1586. | 5.9 | 116 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo. <i>Breast Cancer Research</i> , 2012, 14, R36. | 5.0 | 23 |
| 56 | HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. <i>Cancer Research</i> , 2012, 72, 2672-2682. | 0.9 | 106 |
| 57 | β 1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 229. | 5.0 | 80 |
| 58 | PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. <i>Journal of Clinical Investigation</i> , 2011, 121, 4655-4669. | 8.2 | 110 |
| 59 | Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. <i>Cancer Research</i> , 2010, 70, 7776-7787. | 0.9 | 25 |
| 60 | Distinct Biological Roles for the Akt Family in Mammary Tumor Progression. <i>Cancer Research</i> , 2010, 70, 4260-4264. | 0.9 | 138 |
| 61 | Transcriptional Control of the <i>ERBB2</i> Amplicon by $\text{ERR}\alpha$ and PGC-1 β Promotes Mammary Gland Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 10277-10287. | 0.9 | 78 |
| 62 | A novel role for RhoA in regulating epithelial cell polarity. <i>Genes and Development</i> , 2010, 24, 947-956. | 5.9 | 40 |
| 63 | Identification of a Stat3-Dependent Transcription Regulatory Network Involved in Metastatic Progression. <i>Cancer Research</i> , 2009, 69, 6823-6830. | 0.9 | 96 |
| 64 | PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. <i>Journal of Biological Chemistry</i> , 2009, 284, 19018-19026. | 3.4 | 66 |
| 65 | c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential. <i>Molecular and Cellular Biology</i> , 2009, 29, 5858-5871. | 2.3 | 57 |
| 66 | Integrins in mammary-stem-cell biology and breast-cancer progression – a role in cancer stem cells?. <i>Journal of Cell Science</i> , 2009, 122, 207-214. | 2.0 | 74 |
| 67 | Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression. <i>Cancer Research</i> , 2009, 69, 5057-5064. | 0.9 | 154 |
| 68 | Signal Transduction in Transgenic Mouse Models of Human Breast Cancer – Implications for Human Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 323-335. | 2.7 | 45 |
| 69 | Integrins in breast cancer dormancy. <i>Apmsis</i> , 2008, 116, 677-684. | 2.0 | 23 |
| 70 | ShcA signalling is essential for tumour progression in mouse models of human breast cancer. <i>EMBO Journal</i> , 2008, 27, 910-920. | 7.8 | 131 |
| 71 | Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis. <i>Cancer Research</i> , 2008, 68, 2122-2131. | 0.9 | 45 |
| 72 | Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development. <i>Molecular and Cellular Biology</i> , 2007, 27, 6361-6371. | 2.3 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20302-20307. | 7.1 | 184 |
| 74 | Distinct ErbB-2/Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles. Cancer Research, 2007, 67, 7579-7588. | 0.9 | 23 |
| 75 | Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nature Genetics, 2007, 39, 338-346. | 21.4 | 284 |
| 76 | Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer, 2007, 7, 389-397. | 28.4 | 222 |
| 77 | Multifaceted Roles of Integrins in Breast Cancer Metastasis. Journal of Mammary Gland Biology and Neoplasia, 2007, 12, 135-142. | 2.7 | 79 |
| 78 | β 24 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis. Cell, 2006, 126, 489-502. | 28.9 | 418 |
| 79 | p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/ β 2-Catenin Signaling. Cancer Research, 2006, 66, 8529-8541. | 0.9 | 39 |
| 80 | c-Src-null mice exhibit defects in normal mammary gland development and ERK signaling. Oncogene, 2005, 24, 5629-5636. | 5.9 | 58 |
| 81 | The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation. Oncogene, 2005, 24, 7599-7607. | 5.9 | 68 |
| 82 | Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clinical and Experimental Metastasis, 2005, 22, 47-59. | 3.3 | 182 |
| 83 | Effect of Conditional Knockout of the Type II TGF- β 2 Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis. Cancer Research, 2005, 65, 2296-2302. | 0.9 | 229 |
| 84 | Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling. Cancer Research, 2005, 65, 9695-9704. | 0.9 | 52 |
| 85 | Activation of Akt-1 (PKB- β) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion. Cancer Research, 2004, 64, 3171-3178. | 0.9 | 235 |
| 86 | Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development (Cambridge), 2004, 131, 5551-5560. | 2.5 | 15 |
| 87 | Targeted disruption of β 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell, 2004, 6, 159-170. | 16.8 | 385 |
| 88 | Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants. Breast Cancer Research and Treatment, 2003, 78, 1-6. | 2.5 | 51 |
| 89 | Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene, 2003, 22, 9151-9155. | 5.9 | 28 |
| 90 | Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases. American Journal of Pathology, 2003, 163, 2113-2126. | 3.8 | 912 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8430-8435. | 7.1 | 409 |
| 92 | The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Research, 2003, 63, 3395-402. | 0.9 | 26 |
| 93 | Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Research, 2003, 63, 4920-6. | 0.9 | 53 |
| 94 | Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene, 2002, 21, 890-898. | 5.9 | 94 |
| 95 | Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression. Molecular and Cellular Biology, 2001, 21, 2203-2212. | 2.3 | 262 |
| 96 | Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene, 2001, 20, 7064-7072. | 5.9 | 115 |
| 97 | Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. Journal of Biological Chemistry, 2001, 276, 38921-38928. | 3.4 | 74 |
| 98 | Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer. Molecular and Cellular Biology, 2001, 21, 1540-1551. | 2.3 | 147 |
| 99 | Mammary gland neoplasia: insights from transgenic mouse models. BioEssays, 2000, 22, 554-563. | 2.5 | 40 |
| 100 | Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Medicine, 2000, 6, 306-312. | 30.7 | 511 |
| 101 | Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene, 2000, 19, 1038-1044. | 5.9 | 87 |
| 102 | Transgenic mouse models of human breast cancer. Oncogene, 2000, 19, 6130-6137. | 5.9 | 130 |
| 103 | Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. Molecular and Cellular Biology, 2000, 20, 672-683. | 2.3 | 342 |
| 104 | Oncogene Mediated Signal Transduction in Transgenic Mouse Models of Human Breast Cancer. , 2000, 480, 185-194. | | 2 |
| 105 | Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. Annals of the New York Academy of Sciences, 1999, 889, 45-51. | 3.8 | 23 |
| 106 | A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor β expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Therapy, 1999, 6, 465-474. | 4.6 | 18 |
| 107 | Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene, 1999, 18, 1663-1676. | 5.9 | 138 |
| 108 | The Role of the Epidermal Growth Factor Receptor Family in Mammary Tumorigenesis and Metastasis. Experimental Cell Research, 1999, 253, 78-87. | 2.6 | 168 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein. Molecular and Cellular Biology, 1999, 19, 8169-8179. | 2.3 | 39 |
| 110 | The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members. Oncogene, 1998, 16, 1963-1972. | 5.9 | 26 |
| 111 | Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. International Journal of Cancer, 1998, 77, 640-644. | 5.1 | 226 |
| 112 | Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. International Journal of Cancer, 1998, 77, 937-941. | 5.1 | 58 |
| 113 | CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. Journal of Cellular Physiology, 1998, 176, 206-215. | 4.1 | 249 |
| 114 | Mammalian Grb2 Regulates Multiple Steps in Embryonic Development and Malignant Transformation. Cell, 1998, 95, 793-803. | 28.9 | 345 |
| 115 | Requirement for Both Shc and Phosphatidylinositol 3-kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis. Molecular and Cellular Biology, 1998, 18, 2344-2359. | 2.3 | 189 |
| 116 | Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. , 1998, 77, 937. | | 1 |
| 117 | CD44v3,810 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. Journal of Cellular Physiology, 1998, 176, 206-215. | 4.1 | 4 |
| 118 | Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. International Journal of Cancer, 1997, 72, 197-202. | 5.1 | 33 |
| 119 | Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: An animal model for CEA-directed tumor immunotherapy. , 1997, 72, 197. | | 1 |
| 120 | Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice. , 1996, 15, 44-56. | | 48 |
| 121 | Activated neu Induces Rapid Tumor Progression. Journal of Biological Chemistry, 1996, 271, 7673-7678. | 3.4 | 121 |
| 122 | Transgenic models of breast cancer metastasis. Cancer Treatment and Research, 1996, 83, 71-88. | 0.5 | 15 |
| 123 | Activation Of The Src Family Of Tyrosine Kinases In Mammary Tumorigenesis. Advances in Cancer Research, 1994, 64, 111-123. | 5.0 | 35 |
| 124 | Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 1988, 54, 105-115. | 28.9 | 1,097 |